Skip to main content
SpringerLink
Log in

Myasthenia Gravis: Medications to Avoid

  • Chapter
  • First Online:
The Acute Neurology Survival Guide

  • 1900 Accesses

Abstract

An overview of medications that may worsen the clinical syndrome in patients with myasthenia gravis

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. Medications and myasthenia gravis (a reference for health care professionals). Myasthenia Gravis Foundation of America; 2015. http://www.myasthenia.org/portals/0/draft_medications_and_myasthenia_gravis_for_MGFA_website_8%2010%2012.pdf.

    Google Scholar 

  2. Myasthenia Gravis Foundation of America. Cautionary drugs. New York: Myasthenia Gravis Foundation of America, Inc; 2019.

    Google Scholar 

  3. Jones S, Sorbello A, Boucher R. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf. 2011;34(10):839–47.

    Article  CAS  Google Scholar 

  4. Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature. J Neurol. 2012;259(7):1290–7.

    Article  CAS  Google Scholar 

  5. Jonkers I, Swerup C, Pirskanen R, et al. Acute effects of intravenous injection of beta-adrenoreceptor- and calcium channel at antagonists and agonists in myasthenia gravis. Muscle Nerve. 1996;19(8):959–65.

    Article  CAS  Google Scholar 

  6. de Sousa E, Howard J. More evidence for the association between statins and myasthenia gravis. Muscle Nerve. 2008;38(3):1085–6.

    Article  Google Scholar 

  7. Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019;7:319.

    Article  Google Scholar 

  8. Lee SC, Ho ST. Acute effects of verapamil on neuromuscular transmission in patients with myasthenia gravis. Proc Natl Sci Counc Repub China B. 1987;11(3):307–12.

    CAS  PubMed  Google Scholar 

  9. So EL, Penry JK. Adverse effects of phenytoin on peripheral nerves and neuromuscular junction: a review. Epilepsia. 1981;22(4):467–73.

    Article  CAS  Google Scholar 

  10. Restivo DA, Bianconi C, Ravenni R, et al. ALS and myasthenia: an unusual association in a patient treated with riluzole. Muscle Nerve. 2000;23(2):294–5.

    Article  CAS  Google Scholar 

  11. Frese A, Bethke F, Lüdemann P, et al. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate. J Neurol. 2000;247(9):713.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA

    Megan E. Barra

  2. Department of Neurology, Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    John Y. Rhee

Authors
  1. Megan E. Barra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Y. Rhee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Megan E. Barra .

Editor information

Editors and Affiliations

  1. Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA

    Catherine S.W. Albin

  2. Department of Neurology, Massachusetts General Hospital, Harvard University, Boston, MA, USA

    Sahar F. Zafar

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barra, M.E., Rhee, J.Y. (2022). Myasthenia Gravis: Medications to Avoid. In: Albin, C.S., Zafar, S.F. (eds) The Acute Neurology Survival Guide. Springer, Cham. https://doi.org/10.1007/978-3-030-75732-8_67

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-75732-8_67

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-75731-1

  • Online ISBN: 978-3-030-75732-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation